Review
doi: 10.1016/s0163-7258(96)00103-9.
Platelet prostanoid receptors
Affiliations
- PMID: 9364574
- DOI: 10.1016/s0163-7258(96)00103-9
Item in Clipboard
Review
Platelet prostanoid receptors
Pharmacol Ther.
1996.
Abstract
Prostaglandins (PGs) and thromboxanes are important modulators of platelet activation, and there is strong evidence to support the existence of distinct thromboxane, prostacyclin, PGD2 and PGE2 receptors on the platelet plasma membrane. In this review, each of these platelet prostanoid receptors is discussed in detail, with respect to their receptor pharmacology, molecular biology and signal transduction, and as to any therapeutic implications of the development of specific agonists and/or antagonists. In addition, it considers the possibility that there are separate vascular receptors for 8-epi PGF2 alpha, which are not present on the platelet.
Similar articles
-
Competitive antagonism at thromboxane receptors in human platelets.Br J Pharmacol. 1985 Mar;84(3):595-607. doi: 10.1111/j.1476-5381.1985.tb16139.x. Br J Pharmacol. 1985. PMID: 2580580 Free PMC article.
-
A comparative study of the prostanoid receptor profile of 9 alpha 11 beta-prostaglandin F2 and prostaglandin D2.Br J Pharmacol. 1991 Oct;104(2):541-9. doi: 10.1111/j.1476-5381.1991.tb12465.x. Br J Pharmacol. 1991. PMID: 1665742 Free PMC article.
-
Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.J Pharmacol Exp Ther. 1994 Sep;270(3):1192-6. J Pharmacol Exp Ther. 1994. PMID: 7932171
-
International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress.Pharmacol Rev. 2011 Sep;63(3):471-538. doi: 10.1124/pr.110.003517. Epub 2011 Jul 13. Pharmacol Rev. 2011. PMID: 21752876 Review.
-
Prostanoid receptors and their biological actions.Prog Lipid Res. 1993;32(4):417-34. doi: 10.1016/0163-7827(93)90017-q. Prog Lipid Res. 1993. PMID: 8309950 Review. No abstract available.
Cited by
-
Platelets in liver and renal disease.Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):251-255. doi: 10.1182/asheducation-2016.1.251. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913488 Free PMC article. Review.
-
International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.Pharmacol Rev. 2020 Oct;72(4):910-968. doi: 10.1124/pr.120.019331. Pharmacol Rev. 2020. PMID: 32962984 Free PMC article.
-
Effect of the statin atorvastatin on intracellular signalling by the prostacyclin receptor in vitro and in vivo.Br J Pharmacol. 2004 Sep;143(2):292-302. doi: 10.1038/sj.bjp.0705947. Epub 2004 Aug 23. Br J Pharmacol. 2004. PMID: 15326037 Free PMC article.
-
Future innovations in anti-platelet therapies.Br J Pharmacol. 2008 Jul;154(5):918-39. doi: 10.1038/bjp.2008.151. Epub 2008 Apr 21. Br J Pharmacol. 2008. PMID: 18587441 Free PMC article. Review.
-
Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation.PLoS One. 2012;7(8):e40222. doi: 10.1371/journal.pone.0040222. Epub 2012 Aug 1. PLoS One. 2012. PMID: 22870195 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
